Such system has been further explored by adding a heregulin ligand to bind with high affinity Her2/3 or Her2/4 overexpressed on certain aggressive breast cancers [55] and a recent work reported the delivery of RNAi in HER3+ tumors in vivo [56]. Here, ERBB2 is linked to breast carcinoma.